Daflon 500 + Cialis 20 in Erectile Dysfunction

What Each Drug Does

• Inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cGMP in cavernosal smooth muscle
• Sexual stimulation triggers NO release from endothelium and nerves → activates guanylate cyclase → raises cGMP → smooth muscle relaxation → cavernosal arterial dilation + veno-occlusive mechanism engagement → erection
• Tadalafil sustains the cGMP signal, prolonging and strengthening the erection response
• Half-life ~17.5 hours ("weekend pill") - effective for up to 36 hours per dose
• At 20 mg on-demand, ~59% of men with moderate-severe ED achieve normalization (IIEF-EF ≥26), vs 11% placebo

• Contains diosmin 450 mg + hesperidin 50 mg per tablet
• Primarily a venotonic / venotropic agent approved for chronic venous insufficiency (CVI) and hemorrhoidal disease
• Key pharmacological actions:
  • Increases venous tone (reduces venous distensibility)
  • Reduces capillary permeability and fragility
  • Improves lymphatic drainage
  • Anti-inflammatory (inhibits prostaglandins, thromboxane B2, free radical production)
  • Protects endothelium

Rationale for the Combination

1. Arterial inflow (cGMP-mediated - where tadalafil acts)
2. Veno-occlusive mechanism - as the corpora cavernosa fill and expand, they compress the emissary veins against the tunica albuginea, trapping blood inside (the "corporeal veno-occlusive mechanism")

• Its venotonic effect (increasing venous wall tone, reducing venous distensibility) may help reduce abnormal penile venous outflow
• Its anti-inflammatory and capillary-protective properties may help in ED with a microvascular/endothelial component
• Its enhancement of the NO/cGMP pathway (shown in the 2025 animal study below) complements tadalafil's mechanism

Available Evidence

• Downregulating NF-kB (reducing inflammation)
• Increasing NO and cGMP production in cavernosal tissue
• Upregulating LH, FSH, testosterone, and dopamine
• Improving mounting, intromission, and ejaculation latencies and frequencies

• PDE5 inhibitors are often insufficient as monotherapy in pure venous leak ED
• Venous leak embolization (interventional radiology) is gaining evidence as a next-step treatment when PDE5 inhibitors fail (PMIDs 39638972, 36949182, 41162635)
• No oral pharmacological agent is approved or guideline-recommended for venogenic ED specifically

Who Might Benefit From This Combination

Safety and Drug Interactions

• No direct pharmacokinetic interaction between tadalafil and diosmin/hesperidin is documented
• Daflon is generally very well tolerated (GI upset, nausea, headache - mild, infrequent)
• Tadalafil's standard contraindications apply regardless: nitrates (absolute CI), alpha-blockers (use with caution, hypotension risk), severe cardiovascular disease, recent stroke/MI, uncontrolled hypertension, severe hepatic/renal impairment
• The combination does not amplify hypotensive risk (Daflon has no significant BP-lowering effect)

Practical Notes

• Daflon dosing for venous indications: typically 1 tablet (500 mg) twice daily with meals, or in the acute phase 3 tablets/day x 4 days then 2 tablets/day x 3 days (for hemorrhoids); for chronic use in venous insufficiency it is 2 tablets/day
• There is no established protocol for Daflon dosing specifically in ED - practitioners who use this off-label typically follow the CVI regimen (2 tablets/day long-term)
• Tadalafil 20 mg is the standard on-demand dose for ED; 5 mg daily is an alternative if daily dosing is preferred (also beneficial for LUTS/BPH if present)
• Duration needed to assess Daflon's venotonic effect is likely weeks to months, similar to its use in CVI

Bottom Line

Daflon 500 Overdose

Toxicology Data

What This Means Practically

• The normal therapeutic dose is 1,000 mg/day (two 500 mg tablets)
• Even acute dosing protocols (used for hemorrhoids) go up to 3,000 mg/day for the first 4 days without toxicity concerns
• Taking 5, 10, or even 20 tablets accidentally is extremely unlikely to cause serious harm based on the safety data - but this should never be used as permission to do so
• Side effects even at high doses are typically limited to mild GI upset (nausea, diarrhea, abdominal pain) and rarely headache

If You Took a Large Amount

• It is not considered a dangerous overdose drug in the way that, say, paracetamol or digoxin would be
• If someone took a very large quantity deliberately or accidentally, the approach is standard: observe for GI symptoms, supportive care
• Contact Poison Control (1-800-222-1222 in the US, or your national number) or an emergency department if there is any concern - they will advise based on the amount taken and the person's weight

Important: If you or someone else has taken a large dose and you are concerned, please contact Poison Control or seek medical attention now - the above information is general, not a substitute for real-time clinical assessment.

Mechanism of Action of Daflon 500 (MPFF - Diosmin/Hesperidin)

Overview: Dual Vascular Target

1. The venous/venule wall - venotonic effect
2. The microcirculation - capillary-protective and anti-inflammatory effect

1. Venotonic Mechanism (Venous Wall)

• Diosmin inhibits the degradation of noradrenaline (norepinephrine) at the parietal/perivascular level
• Noradrenaline normally acts on alpha-adrenergic receptors in venous smooth muscle to produce vasoconstriction and increase wall tension
• By prolonging noradrenaline's action, Daflon increases venous wall tone and reduces venous distensibility

2. Microcirculatory Mechanism

A. Capillary Protection

• Increases capillary resistance (measured by angiosterrometry)
• Normalizes capillary permeability - reduces abnormal leaking of plasma proteins into the perivascular space
• Reduces capillary fragility - the capillary wall becomes structurally more resistant

B. Inhibition of Leukocyte Activation and Adhesion

• In venous hypertension, leukocytes (mainly neutrophils) become activated and adhere to the endothelium ("leukocyte trapping")
• Activated leukocytes release cytotoxic substances - free radicals, proteases, and inflammatory mediators - that damage the endothelium and surrounding tissue, leading to edema, skin changes, and ulceration
• Daflon inhibits leukocyte activation, adhesion, and migration through the endothelial wall, breaking this cycle of vascular inflammation

C. Anti-inflammatory Pathway (Arachidonic Acid)

• Inhibits the formation of prostaglandins (via COX pathway inhibition)
• Inhibits thromboxane B2 production
• Inhibits leukotriene B4 (LTB4) production
• Net result: reduces membrane permeability and protects against edema formation

D. Free Radical Scavenging (Antioxidant)

• Diosmin and hesperidin are potent free radical scavengers
• Neutralize reactive oxygen species (ROS) in stimulated polymorphonuclear neutrophils (PMNs)
• Reduce malondialdehyde (MDA) - a marker of lipid peroxidation
• Increase glutathione (GSH) - the main endogenous antioxidant

3. Lymphatic Mechanism

• Improves lymphatic drainage by:
  • Increasing lymph flow rate
  • Increasing lymph oncotic pressure
  • Improving contractility of lymphatic vessels
• This lymphagogue action explains its efficacy against edema even when venous return is only partially restored

4. Endothelial / NO-cGMP Pathway (Relevant to ED Use)

• Diosmin and hesperidin stimulate endothelial cells to release nitric oxide (NO) by raising intracellular calcium
• NO activates guanylate cyclase → raises cGMP → smooth muscle relaxation → vasodilation
• This directly complements tadalafil's mechanism (which prevents cGMP breakdown)
• In animal models, Daflon also:
  • Downregulates NF-kB (master inflammatory transcription factor)
  • Upregulates LH, FSH, testosterone (steroidogenic signaling)
  • Increases dopamine levels

Summary Diagram

DAFLON 500 (Diosmin/Hesperidin)
         │
    ┌────┴────────────────────────────────┐
    │                                      │
VENOUS WALL                        MICROCIRCULATION
    │                                      │
↑ Noradrenaline activity         ↓ Leukocyte adhesion/activation
↑ Venous wall tone               ↓ Prostaglandins / TXB2 / LTB4
↓ Venous capacitance             ↓ Free radicals (ROS scavenging)
↓ Venous distensibility          ↑ Capillary resistance
↓ Venous stasis                  ↓ Capillary permeability
                                  ↑ Lymphatic drainage
                                  ↑ NO / cGMP (endothelial)

Pharmacokinetics (Brief)

• Micronization increases surface area and oral bioavailability significantly vs. non-micronized diosmin
• Extensively metabolized (phenolic acids are active metabolites)
• Elimination: mainly fecal; ~14% urinary
• Half-life: ~11 hours (supports twice-daily dosing)

Natural Sources of Daflon-Like Substances (Diosmin & Hesperidin)

Diosmin - Natural Sources

Plant Sources of Diosmin

Key point: Diosmin is concentrated almost entirely in the outer peel (flavedo) and white pith (albedo) of citrus fruits, NOT in the juice itself. The edible flesh has very little.

Hesperidin - Natural Sources

Hesperidin Content (approximate per 100 g or 100 mL)

Other Hesperidin-Containing Plants

• Peppermint (Mentha piperita) - surprisingly the richest per-weight source when dried
• Plants in the families Fabaceae, Lamiaceae, Betulaceae, and Papilionaceae

The Relationship Between Diosmin and Hesperidin

Hesperidin (abundant in citrus peel)
        │
        │ Dehydrogenation (industrial process)
        ▼
    Diosmin

Other Related Flavonoids Found Alongside Diosmin/Hesperidin

Practical Takeaway

• Eat or zest the citrus peel - this is where the concentration is highest, not the juice
• Bitter orange has the highest flavonoid load of all citrus
• Dried peppermint tea is a surprisingly good source of hesperidin
• However, to reach the therapeutic dose used in Daflon (1,000 mg/day of MPFF), you would need to consume very large quantities of peel - dietary intake alone cannot realistically replicate pharmacological dosing, which is why the micronized concentrated supplement form was developed